Pluri Inc

4DX

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

Investment decisions in overvalued bank drive strong results

Shares fall despite a broadly unchanged outlook.
stocks

Overvalued ASX share hurt by normalising conditions

Investors overly optimisitc about future prospects.
stocks

After earnings, is Amazon stock a buy, a sell, or fairly valued?

With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,109.4052.500.58%
CAC 408,073.79123.611.55%
DAX 4023,979.96410.001.74%
Dow JONES (US)47,021.9534.850.07%
FTSE 1009,788.63106.061.10%
HKSE26,649.06407.231.55%
NASDAQ23,335.51330.971.44%
Nikkei 22550,911.76635.391.26%
NZX 50 Index13,617.4818.270.13%
S&P 5006,783.4854.680.81%
S&P/ASX 2008,835.9044.100.50%
SSE Composite Index4,018.6021.040.53%

Market Movers